Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Myasthenia Gravis
100%
Japan
59%
Inflammatory Myopathy
27%
Migraine
27%
Amyotrophic Lateral Sclerosis
26%
Parkinson's Disease
24%
Neuromyelitis Optica Spectrum Disorder (NMOSD)
23%
Headache
23%
Autoantibodies
21%
Japanese Patients
20%
Myositis
20%
Myopathy
20%
Multiple Sclerosis
16%
Induced Pluripotent Stem Cells (iPSCs)
15%
Eculizumab
15%
Anti-signal Recognition Particle Antibody
14%
Clinical Features
14%
Reductase
14%
Thymoma
13%
Phosphorylation
12%
Neurological Diseases
11%
Cortical Spreading Depression
11%
Ischemic Stroke
11%
Necrotizing Myopathy
11%
Alzheimer's Disease
11%
Alzheime's Disease
11%
Clinical Trials
11%
Ischemic Cerebrovascular Disease
11%
Oligodendrocyte Precursor Cells
11%
Japanese Population
11%
Spreading Depolarization
11%
Acetylcholine Receptor Antibody
10%
Clinical Characteristics
10%
Cerebral Ischemia
10%
95% Confidence Interval
10%
Polymorphism
10%
Demyelination
10%
Satralizumab
10%
Calcitonin Gene-related Peptide Monoclonal Antibody
10%
3-hydroxy-3-methylglutaryl-coenzyme A
10%
Post-marketing Surveillance
9%
CAMP Response Element-binding Protein
9%
Seipin
9%
Interim Analysis
9%
Minimal Manifestations
8%
RNA-binding Protein
8%
Interleukin-6
8%
Ischemia
8%
Cerebrospinal Fluid
8%
Microglia
8%
Multiple Sclerosis Treatment
8%
Neurology
8%
Recirculation
8%
Immune Checkpoint Inhibitors
8%
Adverse Events
7%
Myocarditis
7%
Antisynthetase Syndrome
7%
Prednisolone
7%
Ravulizumab
7%
Parkinson Patients
7%
Healthy Controls
7%
Anti-SRP Myopathy
6%
Placebo-controlled
6%
Rat Brain
6%
Muscle Pathology
6%
Kv1.4
6%
Patients with Parkinson's Disease
6%
Endoplasmic Reticulum Stress (ER stress)
6%
Endoplasmic Reticulum
6%
Treatment Strategy
6%
Age of Onset
6%
Intracerebral Hemorrhage
6%
Muscular Dystrophy
6%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
6%
Limbic Encephalitis
6%
Oligodendrocyte
6%
Randomized Double-blind
6%
Motor Neuron
6%
Muscle Biopsy
6%
Nitric Oxide Production
6%
Japanese Version
6%
Focal Cerebral Ischemia
6%
Long-term Efficacy
6%
Acute Phase
6%
Stem Cell-derived
6%
Neurodegeneration
6%
Placebo
5%
Myasthenic
5%
Temporal Profile
5%
Middle Cerebral Artery
5%
Cerebrovascular Disease
5%
Fused in Sarcoma
5%
Myelination
5%
Reperfusion
5%
Central Nervous System
5%
Therapeutic Strategies
5%
Muscle Weakness
5%
RNA Immunoprecipitation
5%
Aquaporin-4 (AQP4)
5%
Quality of Life
5%
Neuroscience
Myasthenia gravis
65%
Brain Ischemia
46%
Muscle Disorder
38%
Migraine
35%
Parkinson's Disease
31%
Amyotrophic Lateral Sclerosis
31%
Multiple Sclerosis
31%
Autoantibodies
29%
Oligodendrocyte
22%
Alzheimer's Disease
21%
Ischemia
19%
Headache
19%
Spreading Cortical Depression
18%
Astrocyte
18%
In Vivo
17%
Magnetic Resonance Imaging
16%
Microglia
16%
Myositis
16%
Middle Cerebral Artery
16%
Cerebrovascular Accident
14%
Amyloid Protein
13%
Interleukin 6
13%
Signal Recognition Particle
13%
Endoplasmic Reticulum
12%
Nitric Oxide
12%
Stem Cell
12%
Eculizumab
12%
RNA-binding Protein
11%
Neuromyelitis Optica
11%
Glucose
11%
phosphorylation
11%
Striatum
11%
Enzymes
11%
TAR DNA Binding Protein
10%
Blood Plasma
10%
Myelin
10%
Protein Phosphorylation
10%
Single-Photon Emission Computed Tomography
9%
Nervous System Disorder
9%
Cerebrovascular Disease
9%
Neurodegenerative Disorder
9%
Cyclic AMP Responsive Element Binding Protein
9%
Endoplasmic Reticulum Stress
9%
Cyclic Adenosine Monophosphate
9%
Neurodegeneration
9%
Pentose Phosphate
8%
Quality of Life
8%
Auras
8%
Non-Motor Symptoms
8%
Metabolic Pathway
8%
Positron Emission Tomography
8%
Biological Marker
8%
Motor Neuron Disease
8%
Myelinogenesis
8%
Remyelinization
8%
Fluorine-18
7%
Immune Checkpoint Inhibitor
7%
Calcitonin Gene Related Peptide
7%
Receptor
7%
Optogenetics
7%
Encephalitis
7%
Dopamine
7%
Aquaporin 4 Antibody
7%
Serotonin
7%
Central Nervous System
7%
Progenitor Cell
7%
Nucleus
7%
Reactive Oxygen Species
7%
Trigeminal Ganglion
7%
Prednisolone
6%
Oligodendrocyte Progenitor
6%
Cerebral Hemorrhage
6%
Monoclonal Antibody
6%
Steroid
6%
Transcription Factor Nrf2
6%
Behavior (Neuroscience)
6%
Messenger RNA
6%
Cell Signaling
6%
Motor Neuron
5%
Cell Death
5%
3 Hydroxy 3 Methylglutaryl Coenzyme A
5%
Fc Receptor
5%
Microvessel
5%
Microdialysis
5%
Spinal Cord
5%
L-DOPA
5%
Ravulizumab
5%
Protein Binding
5%
Response Element
5%
T Cell
5%
Immunohistochemistry
5%
Calcitonin Gene-Related Peptide
5%
Immunoprecipitation
5%
Hippocampus
5%
Axon
5%
Nuclear Transport
5%
Medicine and Dentistry
Myasthenia gravis
70%
Myopathy
38%
Migraine
31%
Myositis
28%
Headache
23%
Multiple Sclerosis
22%
Diseases
22%
Parkinson's Disease
22%
Autoantibodies
18%
Quality of Life
16%
Prednisolone
15%
Oral
15%
Cerebral Hemorrhage
14%
Alzheimer's Disease
13%
Amyloid Protein
11%
Signal Recognition Particle
11%
Observational Study
10%
Apoplexy
10%
Cross Sectional Study
10%
Oxidoreductase
10%
Magnetic Resonance Imaging
10%
Primary Headache
9%
Remyelination
9%
Single-Photon Emission Computed Tomography
9%
Neurologic Disease
9%
Steroids
9%
Immune Checkpoint Inhibitor
8%
Nivolumab
8%
Myelin
8%
Cohort Analysis
7%
Thymus Cancer
7%
Clinical Feature
7%
Adverse Event
7%
HMG-CoA
7%
Neuromyelitis Optica
7%
Multiple Chronic Conditions
7%
Interim Analysis
7%
Ptosis (Eyelid)
7%
Tau
7%
Iodine 123
7%
Dermatomyositis
6%
Parkinsonism
6%
Prevalence
6%
Levodopa
6%
Brain Ischemia
6%
Muscle Weakness
6%
COVID-19
6%
Monoclonal Antibody
6%
Placebo
6%
Muscle Disease
6%
Antisynthetase Syndrome
6%
Central Nervous System
6%
Thymectomy
6%
Methylprednisolone
6%
Eculizumab
6%
Immunoprecipitation
6%
Capillary
6%
Surgery
6%
Neoplasm
6%
Brain Infarction
5%
Calcitonin Gene Related Peptide
5%
Positron Emission Tomography
5%
Amino Acid Transfer RNA Ligase
5%
Drug Megadose
5%
Pathogenesis
5%
Clinical Trial
5%
Neurology
5%
Mechanical Thrombectomy
5%
Satralizumab
5%
Anti N Methyl D Aspartate Receptor Encephalitis
5%
Brain Disease
5%
Infection
5%
Phosphotransferase
5%
Onset Age
5%
Pathophysiology
5%
Skeletal Muscle
5%
Systemic Lupus Erythematosus
5%
Dopamine Transporter
5%
Glucocorticoid
5%
Muscle Biopsy
5%